[Skip to Navigation]
Comment & Response
April 22, 2020

Initial Monthly Cost of Tafamidis—the Real Price for Patients—Reply

Author Affiliations
  • 1Meyers Primary Care Institute, Worcester, Massachusetts
  • 2Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester
  • 3Center for Cardiac Amyloidosis, Division of Cardiology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York
JAMA Cardiol. 2020;5(7):848. doi:10.1001/jamacardio.2020.0866

In Reply In commenting on our Viewpoint,1 Cuddy et al describe the real price of tafamidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) cared for at their institution. The findings underscore that insurance coverage for prescription medications and patient assistance programs run by pharmaceutical companies do not shield patients from high drug prices. David Mitchell, founder of Patients for Affordable Drugs, has stated, “drugs don’t work if people can’t afford them”2; “innovation and new drugs should not come at prices that bankrupt people…when they are struggling to maintain their health.”3

Add or change institution